ScholarIQanswers from OpenAlex & ORCID
Crystal L. Mackall
ResearcherPublications, citations & collaboration network
Crystal L. Mackall is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Crystal L. Mackall have?
ScholarIQindexed works
Crystal L. Mackall has 511 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Crystal L. Mackall have?
ScholarIQcitation count
Crystal L. Mackall has 27,010 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Crystal L. Mackall?
ScholarIQh-index
Crystal L. Mackall has an h-index of 73 in OpenAlex.
What is the i10-index of Crystal L. Mackall?
ScholarIQi10-index
Crystal L. Mackall has an i10-index of 147 in OpenAlex.
What is the ORCID of Crystal L. Mackall?
ScholarIQorcid
The ORCID for Crystal L. Mackall is on the source record.
What is the OpenAlex record for Crystal L. Mackall?
ScholarIQopenalex
The OpenAlex for Crystal L. Mackall is on the source record.
What are the most-cited papers on Crystal L. Mackall?
ScholarIQmost cited works
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson, Yongzhi Cui, Cindy Delbrook, Steven A. Feldman, Terry J. Fry, Rimas J. Orentas, Marianna Sabatino, Nirali N. Shah, Seth M. Steinberg, D. Stroncek, Nick Tschernia, Constance M. Yuan, Hua Zhang, Ling Zhang, Steven A. Rosenberg, Alan S. Wayne, Crystal L. Mackall
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins, Richard A. Morgan, Steven A. Feldman, James C. Yang, Richard M. Sherry, Mark E. Dudley, John R. Wunderlich, Azam Nahvi, Lee J. Helman, Crystal L. Mackall, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Catherine Lévy, Yong F. Li, Mona El‐Gamil, Susan Schwarz, Carolyn M. Laurençot, Steven A. Rosenberg
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Maryalice Stetler‐Stevenson, Constance M. Yuan, Sneha Ramakrishna, Pamela L. Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates, Haneen Shalabi, Thomas J. Fountaine, Jack F. Shern, Robbie G. Majzner, David F. Stroncek, Marianna Sabatino, Yang Feng, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen, Haiying Qin, Boro Dropulić, Daniel W Lee, Crystal L. Mackall
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah, Steven L. Highfill, Haneen Shalabi, Bonnie Yates, Jianjian Jin, Pamela L. Wolters, Amanda K. Ombrello, Seth M. Steinberg, Staci Martin, Cindy Delbrook, Leah Hoffman, Lauren Little, Anusha Ponduri, Haiying Qin, Haris Qureshi, Alina Dulau‐Florea, Dalia Salem, Hao‐Wei Wang, Constance M. Yuan, Maryalice Stetler‐Stevenson, Sandhya R. Panch, Minh Tran, Crystal L. Mackall, David F. Stroncek, Terry J. Fry
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
Nirali N. Shah, Daniel W. Lee, Bonnie Yates, Constance M. Yuan, Haneen Shalabi, Staci Martin, Pamela L. Wolters, Seth M. Steinberg, Eva H. Baker, Cindy Delbrook, Maryalice Stetler‐Stevenson, Terry J. Fry, David F. Stroncek, Crystal L. Mackall